This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pfützner, A. Articles by Forst, T. Search for Related Content PubMed PubMed Citation Articles by Pfützner, A. Articles by Forst, T.

Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control

Results From the Pioneer Study

Andreas Pfützner, MD, PhD^_*,,_*, Nikolaus Marx, MD, Georg Lübben, MD, Matthias Langenfeld, MD^_*, Daniel Walcher, MD, Thomas Konrad, MD^|| and Thomas Forst, MD^_*

^_* IKFE—Institute for Clinical Research and Development, Mainz, Germany
University of Applied Sciences, Rheinbach, Germany
University Hospital, Ulm, Germany
Takeda Pharma GmbH, Aachen, Germany
^|| ISF—Institute for Metabolic Research, Frankfurt, Germany

View larger version (21K): [in a new window]   Figure 1 Mean of individual percent changes from baseline in selected biochemical and clinical cardiovascular risk markers. hsCRP = high-sensitivity C-reactive protein; IMT = carotid intima media thickness; MCP = monocyte chemoattractant protein; MMP = matrix metalloproteinase.

View larger version (37K): [in a new window]   Figure 2 Stratification of percent changes in the cardiovascular risk markers according to therapeutic response (responders: absolute change in HbA1c 0.6%; nonresponders: absolute change in HbA1c <0.6%). Abbreviations as in Figure 1.